Prof. Mark Weiser serves as the Chairman of the Psychiatric Division at Sheba Medical Center since 2006 and does research in schizophrenia, epidemiological studies and clinical trials. He is committed to utilizing innovative research in clinical psychiatry.
Education:
1992-1996, Psychotherapy, Tel Aviv university, Tel Aviv, Israel
1990-1995, Psychiatry, Resident, Shalvata Mental Health Center, Hod Hasharon, Israel
1990-1992, Psychiatry, Post-graduate studies, Tel Aviv university, Tel Aviv, Israel
1983-1988, Medicine, M.D., Hebrew university, Jerusalem, Israel
1980-1983, Biology, B.Sc, Hebrew university, Jerusalem, Israel
Employment History Experience:
1996-Present, Psychiatric Division, Sheba Medical Center, Tel Hashomer, Israel
1990-1996, Psychiatry, Shalvata Mental Health Center, Hod Hasharon, Israel
Academic Appointments:
1997-Professor, Department of Psychiatry, Tel Aviv University School of Medicine
Membership in Professional/ Scientific Societies:
American College of Neuropsychopharmacology
European College of Neuropsychopharmacology
Schizophrenia International Research Society
International Society for CNS Clinical Trials and Methodology
The Stanley Medical Research Institute (SMRI)
Awards, Citations, Honors, Competitive Fellowships:
2023, INTENSIFY: intensified pharmacological treatment for schizophrenia, MDD and BD. European Commission, Horizon
2021. Israeli PI 60,000€
2022, Long term side effects of antipsychotic medications. 100,000$ Merck PI
2021, Palmitoylethanolamide (PEA) vs placebo for Major Depression Stanley Medical Research Institute, 1,000,000$ PI
2020, Cannabidiol for schizophrenia, Welcome Trust Fund. Israel PI, 250,000 GBP
2019, Epigenetic markers for post partum depression-joint project with Johns Hopkins PI 80,000$
2018, Estradiol Patches for females aged 38-45 with schizophrenia. Stanley Medical Research Institute, 1,034,000$ PI
2018, Income of psychiatric patients, project with the Israeli Social Security Institute 100,000 Nis
2017, ALKS 3831 for schizophrenia. Alkermes. Israel country coordinator. 300,000$
2015, PSYSCAN project. European Union. Israel Coordinator. 120,000€
2014, Nitroprusside for Schizophrenia, Stanley Medical Research Institute. PI, 250,000$
2014, Estradiol for schizophrenia. Stanley, Medical Research Institute. PI. 1,843,700$
2014, European Long-acting Antipsychotics in Schizophrenia Trial (EULAST). EGRIS. Israel Coordinator. 400,000€
2014, Effect of atypical antipsychotic drugs on male fertility: potential testosterone and estradiol modulation. NARSAD young investigator grant. Mentor. 60,000$
2013, Aspirin for schizophrenia, Stanley Medical Research Institute. PI, 1,400,000$
2012, Simvastatin and Naproxen for schizophrenia, Stanley Medical Research Institute. PI, 1,800,000$
2011, Valnoctamide for acute mania. Stanley Medical Research Institute. PI, 2,400,000$
2011, Oxytocin for schizophrenia Stanley Medical Research Institute. PI, 400,000$
2010, Allopurinol for mania: A randomized trial administering allopurinol vs. placebo as add-on to mood stabilizers and/or antipsychotics in patients in a bipolar manic episode. Stanley Medical Research Institute. PI, 2,100,000$
2010, Optimization of Treatment and Management of Schizophrenia in Europe. European Community, Israeli -PI, 400,000€
2010, Minocycline, Aspirin and Pramipexole in schizophrenia, PI, Stanley Medical Research Institute. PI, 3,400,000$
2010, Raloxifene in schizophrenia, Stanley Medical Research Institute. PI, 1,300,000$
2008, Safety, tolerability, efficacy and pharmacokinetics of Sarcosine at 2, 4, and 8 gm/d in schizophrenia patients: a dose escalation study. National Alliance for Research on Schizophrenia and Affective Disorders, Independent Investigator Award. 100,000$
2008, Allopurinol for Schizophrenia and Schizoaffective disorder. Stanley Medical Research Institute. PI, 2,000,000$
2008, Sarcosine for Schizophrenia, Project Leader, 900,000$. Part of a Conte Center Grant, Daniel Javitt PI
2007, Sertindole vs Risperidone for Cognition in Schizophrenia. Lundbeck, 220,000€. PI
2006, Escitalopram and sleep architecture in patients with Major Depressive Disorder, Lundbeck, 43,000$ Investigator
2006, Add on Simvastatin in Schizophrenia trail (ASSISST), Stanley Medical Research Institute, Israeli PI, 150,000$
2004, D-Serine adjutant pharmacotherapy for the treatment of schizophrenia Stanley Medical Research Institute, 1,750,000$, PI
2003, National Alliance for Research on Schizophrenia and Affective Disorders, Young Investigator Award: Meningitis and Risk for Schizophrenia 60,000$. PI
2003, Stanley Center Grant 2003-2005. 300,000$. PI
2003, Cognitive Impairment as Endo-phenotype for schizophrenia, NIMH 2003-2008; Israeli PI 1,800,000$
2000, National Alliance for Research on Schizophrenia and Affective Disorders, Young Investigator Award: Assessing Recall Bias in Schizophrenia: Comparing Retrospective Data with Data Collected Pre-morbidly. 60,000$. PI
1999, Stanley Foundation: Cognitive and behavioral abnormalities predicting hospitalization for schizophrenia. 150,000$. Co-PI
1999, Israeli Ministry of Health: Ascertaining the cost of discharging psychiatric patients to home care by family members. 55,000$. Investigator
1998, Eli Lilly: The use of Visuo-Manual Testing in comparing extrapyramidal side effects of Olanzapine and Risperidone. 51,000$. PI
Publications:
Here is a link to the publications of Prof. Mark Weiser in PubMed: a database of scientific articles in the fields of medicine and life sciences
